Mark Fleury, PhD, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.
Mark Fleury, PhD, principal of policy development, American Cancer Society Cancer Action Network, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.
The COVID-19 pandemic presented a significant need to rapidly advance the utility of decentralized clinical trials, says Fleury. Historically, the oncology field anticipated that decentralized clinical trials would be an important aspect of offering patients more accessible and convenient clinical trial options away from the conventional clinical trial setting, Fleury explains.
It is important that the lessons learned from the pandemic, as well as the use of tools developed for decentralized clinical trials, continue even beyond the COVID-19 pandemic, concludes Fleury.